886,499 Shares in Globus Medical, Inc. $GMED Purchased by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 886,499 shares of the medical device company’s stock, valued at approximately $70,042,000. Globus Medical accounts for about 1.9% of Paradigm Capital Management Inc. NY’s holdings, making the stock its 13th biggest position.

Other hedge funds also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Globus Medical by 71,618.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after buying an additional 715,470 shares during the period. WCM Investment Management LLC acquired a new stake in Globus Medical during the 1st quarter worth $16,965,000. SG Americas Securities LLC raised its position in shares of Globus Medical by 241.1% during the 1st quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company’s stock valued at $29,333,000 after acquiring an additional 240,642 shares during the last quarter. Artemis Investment Management LLP lifted its stake in shares of Globus Medical by 43.7% in the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock valued at $64,487,000 after purchasing an additional 224,587 shares during the period. Finally, Hyperion Capital Advisors LP acquired a new position in shares of Globus Medical in the 4th quarter valued at $12,822,000. Institutional investors own 95.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GMED shares. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Royal Bank Of Canada cut their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. BMO Capital Markets initiated coverage on Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Stock Down 3.2%

Shares of NYSE GMED opened at $84.11 on Tuesday. Globus Medical, Inc. has a twelve month low of $54.15 and a twelve month high of $101.40. The stock has a market cap of $11.29 billion, a price-to-earnings ratio of 21.51, a P/E/G ratio of 1.40 and a beta of 0.95. The company’s fifty day moving average is $80.71 and its 200-day moving average is $84.72.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts anticipate that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Insider Transactions at Globus Medical

In related news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.